Antitumour activity of N-[[1-[[2-(diethylamino)ethyl]amino]-9-oxo-9H-thioxanthen-4-yl]methyl]methanesulfonamide (WIN33377) and analogues
Corbett T, Lowichik N, Pugh S, Polin L, Panchapor C, White K, Knight J, Demchik L, Jones J, Jones L, Biernat L, Lorusso P, Foster B, Heilbrun L, Rake J, Mattes K, Perni R, Powles R, Hlavac A, Wentland M, Coughlin S, Baker L, Valeriote F. Antitumour activity of N-[[1-[[2-(diethylamino)ethyl]amino]-9-oxo-9H-thioxanthen-4-yl]methyl]methanesulfonamide (WIN33377) and analogues. Expert Opinion On Investigational Drugs 1994, 3: 1281-1292. DOI: 10.1517/13543784.3.12.1281.Peer-Reviewed Original ResearchLiver toxicityAntitumour activityClinical trialsPhase I clinical trialSevere liver toxicityEfficacious dose levelsPreclinical modelsDose levelsBetter efficacyWeekly scheduleAntischistosomal agentsDay scheduleHycanthoneM2 levelToxicityTrialsMost analoguesAgentsRecovery timeVariety of analoguesGroupActivityMiceDoseRandomized clinical trial of mitomycin-C with or without pretreatment with WR-2721 in patients with advanced colorectal cancer
Poplin E, LoRusso P, Lokich J, Gullo J, Leming P, Schulz J, Veach S, McCulloch W, Baker L, Schein P. Randomized clinical trial of mitomycin-C with or without pretreatment with WR-2721 in patients with advanced colorectal cancer. Cancer Chemotherapy And Pharmacology 1994, 33: 415-419. PMID: 8306416, DOI: 10.1007/bf00686271.Peer-Reviewed Original ResearchConceptsColorectal cancerMyelosuppressive potentialRefractory colorectal cancerMetastatic colorectal cancerAdvanced colorectal cancerRandomized clinical trialsUse of mitomycinRefractory colorectal carcinomaMitomycin therapyPlatelet nadirsHematologic toxicityPrincipal toxicityPartial responseClinical trialsColorectal carcinomaSame dosePatientsMitomycinCancerThrombocytopeniaTherapyToxicityGroupPretreatmentFluorouracil